Literature DB >> 30377197

Right Time and Place for IL12: Targeted Delivery Stimulates Immune Therapy.

H Kim Lyerly1,2,3, Takuya Osada4, Zachary C Hartman4,2.   

Abstract

Systemic IL12 therapy has potent antitumor effects, but clinical delivery of this potent cytokine has been complicated by systemic toxicity. A novel strategy to deliver IL12 to the tumor microenvironment appears promising in a first-in-human study, appearing to stimulate tumor-specific adaptive immune responses with minimal systemic toxicity.See related article by Strauss et al., p. 99. ©2018 American Association for Cancer Research.

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30377197     DOI： 10.1158/1078-0432.CCR-18-2819

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  6 in total

Review 1.  Localized Interleukin-12 for Cancer Immunotherapy.

Authors:  Khue G Nguyen; Maura R Vrabel; Siena M Mantooth; Jared J Hopkins; Ethan S Wagner; Taylor A Gabaldon; David A Zaharoff
Journal:  Front Immunol       Date:  2020-10-15       Impact factor: 7.561

2.  Intratumoral Plasmid IL12 Expands CD8+ T Cells and Induces a CXCR3 Gene Signature in Triple-negative Breast Tumors that Sensitizes Patients to Anti-PD-1 Therapy.

Authors:  Melinda L Telli; Hiroshi Nagata; Irene Wapnir; Chaitanya R Acharya; Kaitlin Zablotsky; Bernard A Fox; Carlo B Bifulco; Shawn M Jensen; Carmen Ballesteros-Merino; Mai Hope Le; Robert H Pierce; Erica Browning; Reneta Hermiz; Lauren Svenson; Donna Bannavong; Kim Jaffe; Jendy Sell; Kellie Malloy Foerter; David A Canton; Christopher G Twitty; Takuya Osada; H Kim Lyerly; Erika J Crosby
Journal:  Clin Cancer Res       Date:  2021-02-16       Impact factor: 13.801

3.  Genetically engineered and enucleated human mesenchymal stromal cells for the targeted delivery of therapeutics to diseased tissue.

Authors:  Huawei Wang; Christina N Alarcón; Bei Liu; Felicia Watson; Stephen Searles; Calvin K Lee; Jeremy Keys; Willie Pi; Dale Allen; Jan Lammerding; Jack D Bui; Richard L Klemke
Journal:  Nat Biomed Eng       Date:  2021-12-20       Impact factor: 29.234

4.  Generation and in vivo validation of an IL-12 fusion protein based on a novel anti-human FAP monoclonal antibody.

Authors:  Lisa Nadal; Frederik Peissert; Abdullah Elsayed; Tobias Weiss; Thomas Look; Michael Weller; Geny Piro; Carmine Carbone; Giampaolo Tortora; Mattia Matasci; Nicholas Favalli; Riccardo Corbellari; Cesare Di Nitto; Eleonora Prodi; Chiara Libbra; Simone Galeazzi; Claudiopietro Carotenuto; Cornelia Halin; Emanuele Puca; Dario Neri; Roberto De Luca
Journal:  J Immunother Cancer       Date:  2022-09       Impact factor: 12.469

Review 5.  Interferon-γ: teammate or opponent in the tumour microenvironment?

Authors:  Angela M Gocher; Creg J Workman; Dario A A Vignali
Journal:  Nat Rev Immunol       Date:  2021-06-21       Impact factor: 53.106

6.  Genetically engineered macrophages persist in solid tumors and locally deliver therapeutic proteins to activate immune responses.

Authors:  Katherine J Brempelis; Courtney M Cowan; Shannon A Kreuser; Kevin P Labadie; Brooke M Prieskorn; Nicole A P Lieberman; Chibawanye I Ene; Kara W Moyes; Harrison Chinn; Kole R DeGolier; Lisa R Matsumoto; Sara K Daniel; Jason K Yokoyama; Amira D Davis; Virginia J Hoglund; Kimberly S Smythe; Stephanie D Balcaitis; Michael C Jensen; Richard G Ellenbogen; Jean S Campbell; Robert H Pierce; Eric C Holland; Venu G Pillarisetty; Courtney A Crane
Journal:  J Immunother Cancer       Date:  2020-10       Impact factor: 13.751
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.